Alvimedica’s 2-mm Cre8 Evo DES Receives CE Mark Approval
February 4, 2019—Alvimedica announced European CE Mark approval of its 2-mm Cre8 EVO drug-eluting stent, further enlarging the company's polymer-free, amphilimus-eluting stent portfolio and offering physicians more extensive treatment coverage for patients with complex coronary artery disease.
According to the company, the device’s ultra-thin 70 µm total stent strut minimizes metal volume in small coronaries, and its design meets the specific device deliverability, conformability to the vessel, and mechanical performance required for 2-mm vessels. Because of its unique cell geometry, the device can be implanted in challenging tapered and tortuous vessels and side branches.
Leyla Alaton, President and CEO of Alvimedica, commented, “We are taking the challenge to develop devices that answer the real, everyday clinical unmet needs in a global scenario. The patient population suffering from coronary disease increases every year, [and] its clinical need may be different according to the clinical conditions, disease location, and geographical area.”